short term uw
expect ew share tomorrow heel better-than-expect tavr
result came better we/th street expect upsid driven
transcathet aortic valv replac tavr tavr sale
underli basi beat consensus/our estim manag said
couldnt pin-point singular reason believ low risk trial result releas mid-
march may help drive market adopt ahead fda label indic
ew expect anticip step-up rate growth
centera discontinu problem edward announc discontinu
self-expand centera tavr program cite time resourc requir
optim deliver well expand indic match sapien
valv signific given trial result sale trend sapien balloon-
expand tavr see problem context ew
singl tavr product risk sapien valv thrombosi end real issu
focu analyst call rais tavr guidanc ew
comment expect tavr sale around top prior rang
given ytd perform pend indic expans
estimate analyst question manag guidanc note last quarter
sound track given reduc guidanc think manag
play one right point top end given centera discontinu
competit pressur ramp past tavr volatil seen quarter-to-quart
updat updat model reflect result latest think
outlook also updat pt methodolog reflect target pe
unchang ep vs prior maintain
ew quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
sale strong driven sale ep come street/ estim
strong quarter mainli driven higher tavr sale underli
basi edward rais tavr underli sale growth guidanc top end
rang tmtt sale show solid increas
ep street estim estim
slightli upper end guidanc rang edward rais
full year ep guidanc rang guidanc compar
favor street expect billion billion rang
expect stock trade favor total result net/net noth
chang view outlook stock
addit detail quarter
million except per share data chang sale constant currenc underli basi unless otherwis note
tavr sale well street estim
estim tavr sale underli basi
underli growth
critic sale y/i street/
estim growth attribut hemospher sale us europ
tmtt sale sale slightli estim sale
show solid step tmtt sale attribut continu
roll-out pascal europ sale perform reflect higher sale
despit strong tavr sale anticip fda label indic expans
low-risk patient manag rais guidanc rather
around top previou rang
sale billion underli basi underli growth
divis transcathet aortic structur heart critic
gross margin y/i driven favor fx impact product
mix partial off-set invest global suppli chain expans
sg sale y/i driven transcathet structur heart field
 sale y/i edward continu invest clinic
trial transcathet structur heart program
oper margin y/i
adjust tax rate y/i includ benefit
adjust ep street estim
edward expect sale compar favour consensu billion expect ep
consensu
edward expect total sale rang underli growth top end prior rang
underli basi ew expect transcathet aortic valv replac tavr growth top end rang
sale billion surgic structur heart growth sale million critic growth
sale around top million transcathet mitral tricuspid therapi tmtt sale still expect
fx headwind expect edward rais adjust ep guidanc
actual million salesrptdunderlyingtranscathet aortic mitral tricuspid heart street divis estim streetaccount els refinitivyoy barclay edward lifesci corp
pleas see note publish kstew call note want
analyst question rais tavr guidanc link addit takeaway
updat model avail barclay live
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
